Tomorrow: Thursday, November 8

Thursday, November 8, 2007 General News J E 4
CAMBRIDGE, Mass., Nov. 7 The one-day November 8 MASSOpportunities Investor Conference (MASS Opps) features 32 presentations byinnovative private and public biotechnology companies marked for growth in2008. The event showcases six distinguished panels that will cover timely"future of science" themes, insights into biotechnology financing, and stateand federal policy challenges in the coming year. Three keynote addressesround out the exciting and informative program.

Following last year's MASS Opps, presenting companies announced $198million in new venture capital fundraising. Two companies announced IPOstotaling more than $107 million, and twelve alliances/partnerships were formedincluding a $1 billion licensing deal.

The ninth annual MASS Opps, New England's largest biotechnology investorforum, is a robust experience that brings together over 500 CEO's, portfoliomanagers, venture capitalists, healthcare analysts, and professionals from theacademic, clinical, and technology transfer communities who support emergingand developing biotechnology companies.


Acceleron Pharma, Aphios Corporation, BIND Biosciences, BioVex, DynogenPharmaceuticals, Ensemble Discovery Corporation, Epitome Biosystems,Genstruct, Gwathmey, Inotek Pharmaceuticals, Logical Therapeutics, MolecularBiometrics, Primera Biosystems, Targeted Cell Therapies, TransMolecular


Alnylam Pharmaceuticals, Alseres Pharmaceuticals, ArQule, CombinatorRx,Dyax Corp, EXACT Sciences Corp., Helicos Biosciences Corporation, InfinityPharmaceuticals, Momenta Pharmaceuticals, NitroMed, Oscient PharmaceuticalsCorporation, Pro-Pharmaceuticals, SolMap Pharmaceuticals, SyntaPharmaceuticals, Targanta Therapeutics, Vertex Pharmaceuticals, ZIOPHARMOncology

The Massachusetts Biotechnology Council (MBC) is the nation's oldestbiotechnology trade association. Founded in 1985, the MBC is a not-for-profitorganization that represents and provides services and support for theMassachusetts biotechnology industry. The MBC is committed to advancing thedevelopment of critical new science, technology and medicines that benefitpeople worldwide. Representing over 500 biotechnology companies, academicinstitutions, research hospitals, and service organizations involved in lifesciences and health care, the MBC works to advance policy and promoteeducation, while providing member programs and events, industry information,and services.INDUSTRY PANELS * New Wrinkles on Neurodegenerative Disease * Tools are Back: New Technologies Driving Innovation * The Coming Wave in Nano-Biotechnology * Deal Making and M&A Exits * Funding Early Stage Technology: Corporate Symbiosis, Incubators and New Venture Approaches * A Year of Living Dangerously - Why an Onslaught of New Federal Legislation Presents Biotechnology Its Greatest Challenge Ever KEYNOTE SESSIONS Opening Plenary: Opportunities on the Horizon Moderator: Jeffrey M. Wiesen, Partner & Chairman, Biotechnology Practice, Mintz Levin Keynote Lunch: The Role of Innovation in Biotechnology Dr. Stelios Papadopoulos, Noted former investment banker and biotechnology company builder Closing Plenary: The $1-$3 billion Biotech Funding Puzzle: Putting the Pieces Together Moderator: Glen Giovannetti, Global Biotechnology Leader, Ernst & Young Biotechnology Center

SOURCE Massachusetts Biotechnology Council


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
AIDS Vaccine Advocacy Coalition Calls for AIDS Vac...
Central Mississippi Steel Magnolias Affiliate of S...